• Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021

    المصدر: Nasdaq GlobeNewswire / 09 يوليو 2021 08:36:31   America/New_York

    CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President & Chief Executive Officer, is scheduled to participate in a panel at the William Blair Biotech Focus Conference 2021, which is being held virtually from July 14-15.

    Panel Details:
    Title: Next Generation Small Molecules in Oncology
    Panel date and time: Thursday, July 15, 9:00 a.m. ET

    A live webcast of the panel can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com.

    About Foghorn Therapeutics

    Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

    Media Contact:

    Fanny Cavalié, Foghorn Therapeutics
    fcavalie@foghorntx.com

    Gregory Kelley, Ogilvy
    gregory.kelley@ogilvy.com

    Investor Relations Contact:

    Allan Reine, Foghorn Therapeutics
    areine@foghorntx.com

    Hans Vitzthun, LifeSci Advisors
    617-430-7578
    hans@lifesciadvisors.com


    Primary Logo

شارك على،